Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins: Miniperspective

ZINC − A Free Database of Commercially Available Compounds for Virtual Screening

Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058 · see citing works

New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays

Baell, J. B., & Holloway, G. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901137j · Cited by 3,963 · see citing works

Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand

Xiong, J.-P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S. L., & Arnaout, M. A. (2002) · Science · doi:10.1126/science.1069040 · Cited by 1,617 · see citing works

Integrins

Barczyk, M., Carracedo, S., & Gullberg, D. (2010) · Cell and Tissue Research · doi:10.1007/s00441-009-0834-6 · Cited by 1,512 · see citing works

Crystal Structure of the Extracellular Segment of Integrin αVβ3

Xiong, J.-P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Goodman, S. L., & Arnaout, M. A. (2001) · Science · doi:10.1126/science.1064535 · Cited by 1,278 · see citing works

Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin

Tamkun, J. W., DeSimone, D. W., Fonda, D., Patel‐King, R. S., Buck, C. A., Horwitz, A. F., & Hynes, R. O. (1986) · Cell · doi:10.1016/0092-8674(86)90744-0 · Cited by 871 · see citing works

Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation

Mas‐Moruno, C., Rechenmacher, F., & Kessler, H. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794728639 · Cited by 649 · see citing works

Breaking the Integrin Hinge

Hughes, P. E., Díaz‐González, F., Leong, L., Wu, C., McDonald, J. A., Shattil, S. J., & Ginsberg, M. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.12.6571 · Cited by 571 · see citing works

Structure of a Complete Integrin Ectodomain in a Physiologic Resting State and Activation and Deactivation by Applied Forces

Zhu, J., Luo, B., Xiao, T. S., Zhang, C., Nishida, N., & Springer, T. A. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.11.018 · Cited by 503 · see citing works

Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors

Reynolds, A. R., Hart, I. R., Watson, A. R., Welti, J. C., Silva, R. G., Robinson, S. D., Violante, G. D., Gourlaouen, M., Salih, M., Jones, M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1941 · Cited by 494 · see citing works

Ligands “activate” integrin αIIbβ3 (platelet GPIIb-IIIa)

Du, X., Plow, E. F., Frelinger, A. L., O’Toole, T. E., Loftus, J. C., & Ginsberg, M. H. (1991) · Cell · doi:10.1016/0092-8674(91)90458-b · Cited by 485 · see citing works

Integrins as therapeutic targets: lessons and opportunities

Cox, D. M., Brennan, M., & Moran, N. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3266 · Cited by 456 · see citing works

Structure and mechanics of integrin-based cell adhesion

Arnaout, M. A., Goodman, S. L., & Xiong, J.-P. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.08.002 · Cited by 403 · see citing works

Integrin-based therapeutics: biological basis, clinical use and new drugs

Ley, K. F., Rivera–Nieves, J., Sandborn, W. J., & Shattil, S. J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.10 · Cited by 399 · see citing works

Integrin inside-out signaling and the immunological synapse

Springer, T. A., & Dustin, M. L. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.10.004 · Cited by 392 · see citing works

Inside-out, outside-in, and inside–outside-in: G protein signaling in integrin-mediated cell adhesion, spreading, and retraction

Shen, B., Delaney, M. K., & Du, X. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.08.011 · Cited by 229 · see citing works

The regulation of integrin function by divalent cations

Zhang, K., & Chen, J. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.18702 · Cited by 224 · see citing works

A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma

Hersey, P., Sosman, J. A., O'Day, S. J., Richards, J. M., Bedikian, A. Y., Gonzalez, R. C., Sharfman, W. H., Weber, R. W., Logan, T. F., Buzoianu, M., et al. (2010) · Cancer · doi:10.1002/cncr.24821 · Cited by 190 · see citing works

Non-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp

Egbertson, M. S., Chang, C. T.-C., Duggan, M. E., et al. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00042a007 · Cited by 182 · see citing works

A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer

Bell‐McGuinn, K. M., Matthews, C. M., Ho, S. N., Barve, M. A., Gilbert, L., Penson, R. T., Lengyel, E. R., Palaparthy, R., Gilder, K. M., Vassos, A. B., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.12.362 · Cited by 179 · see citing works

Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel

Coller, B., Cheresh, D., Asch, E., et al. (1991) · Blood · doi:10.1182/blood.v77.1.75.75 · Cited by 166 · see citing works

Effect of L-000845704, an αVβ3 Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women

Murphy, M. G., Cerchio, K., Stoch, S. A., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2126 · Cited by 137 · see citing works

Structural basis for pure antagonism of integrin αVβ3 by a high-affinity form of fibronectin

Agthoven, J. F. V., Xiong, J.-P., Alonso, J. L., Rui, X., Adair, B. D., Goodman, S. L., & Arnaout, M. A. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2797 · Cited by 135 · see citing works

Regulation of integrin-type cell adhesion receptors by cytokines.

Santala, P., & Heino, J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)54526-9 · Cited by 131 · see citing works

Discovery of Small Molecule Integrin αvβ3 Antagonists as Novel Anticancer Agents

Dayam, R., Aiello, F., Deng, J. N., Wu, Y., Garofalo, A., Chen, X. S., & Neamati, N. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051296s · Cited by 111 · see citing works

Closed headpiece of integrin αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening

Zhu, J., Zhu, J., Negri, A., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281154 · Cited by 108 · see citing works

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

Delbaldo, C., Raymond, É., Vera, K., Hammershaimb, L., Kaucic, K., Lozahic, S., Marty, M. E., & Faivre, S. J. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9077-0 · Cited by 101 · see citing works

Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study

Bhatt, D. L., Lee, B. I., Casterella, P. J., et al. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02631-1 · Cited by 99 · see citing works

Structure-Guided Design of a High-Affinity Platelet Integrin α IIb β 3 Receptor Antagonist That Disrupts Mg 2+ Binding to the MIDAS

Zhu, J., Choi, W.-S., McCoy, J. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003576 · Cited by 97 · see citing works

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome

Weller, M., Nabors, B., Gorlia, T., Leske, H., Rushing, E. J., Bady, P., Hicking, C., Perry, J., Hong, Y.-K., Roth, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7588 · Cited by 89 · see citing works

RUC-4

Li, J., Vootukuri, S., Shang, Y., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303724 · Cited by 88 · see citing works

A Mechanistic Model for Paradoxical Platelet Activation by Ligand-Mimetic αIIbβ3(GPIIb/IIIa) Antagonists

Bassler, N., Loeffler, C., Mangin, P., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000255307.65939.59 · Cited by 85 · see citing works

αIIbβ3: structure and function

Coller, B. S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12915 · Cited by 76 · see citing works

Volociximab in cancer

Almokadem, S., & Belani, C. P. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.646985 · Cited by 73 · see citing works

Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban

King, S., Short, M. R., & Harmon, C. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.07.008 · Cited by 71 · see citing works

Application of high-throughput screening to identify a novel αIIb-specific small- molecule inhibitor of αIIbβ3-mediated platelet interaction with fibrinogen

Blue, R. C., Murcia, M., Karan, C., et al. (2007) · Blood · doi:10.1182/blood-2007-08-105544 · Cited by 67 · see citing works

Oral GPIIb / IIIa Antagonists: What Went Wrong?

Cox, D. M. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384673 · Cited by 66 · see citing works

One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial

Ndrepepa, G., Kastrati, A., Mehilli, J., Neumann, F.-J., ten Berg, J. M., Bruskina, O., Dotzer, F., Seyfarth, M., Pache, J., Dirschinger, J., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm562 · Cited by 62 · see citing works

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma

Gerstner, E. R., Ye, X., Duda, D. G., Levine, M. A., Mikkelsen, T., Kaley, T. J., Olson, J. J., Nabors, B., Ahluwalia, M. S., Wen, P. Y., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov085 · Cited by 61 · see citing works

Antithrombotics in Acute Coronary Syndromes

Bonaca, M. P., Steg, P. G., Feldman, L. J., Canales, J. F., Ferguson, J. J., Wallentin, L. C., Califf, R. M., Harrington, R. A., & Giugliano, R. P. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.03.083 · Cited by 59 · see citing works

Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis

Pickarski, M., Gleason, A., Bednár̂, B., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.3910 · Cited by 54 · see citing works

Three-dimensional reconstruction of intact human integrin αIIbβ3: new implications for activation-dependent ligand binding

Choi, W. S., Rice, W. J., Stokes, D. L., et al. (2013) · Blood · doi:10.1182/blood-2013-04-499194 · Cited by 52 · see citing works

Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases

Rosenthal, M. A., DAVIDSON, P., Rolland, F., et al. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2009.01266.x · Cited by 50 · see citing works

Integrin Priming Dynamics: Mechanisms of Integrin Antagonist-Promoted αIIbβ3:PAC-1 Molecular Recognition

Hantgan, R. R., & Stahle, M. C. (2009) · Biochemistry · doi:10.1021/bi900475k · Cited by 45 · see citing works

Oral Glycoprotein IIb/IIIa Inhibitors

Chew, D. P., Bhatt, D. L., & Topol, E. J. (2001) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200101060-00002 · Cited by 40 · see citing works

Assessment of the Integrin α5β1 Antagonist JSM6427 in Proliferative Vitreoretinopathy Using In Vitro Assays and a Rabbit Model of Retinal Detachment

Zahn, G., Volk, K., Lewis, G. P., Vossmeyer, D., Stragies, R., Heier, J. S., Daniel, P. E., Adamis, A. P., Chapin, E. A., Fisher, S. K., et al. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3575 · Cited by 37 · see citing works

Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel αIIb-specific αIIbβ3 antagonist

Blue, R. C., Kowalska, M. A., Hirsch, J. D., et al. (2009) · Blood · doi:10.1182/blood-2008-08-169243 · Cited by 34 · see citing works

Will integrin inhibitors have proangiogenic effects in the clinic?

Weller, M., Reardon, D. A., Nabors, B., et al. (2009) · Nature Medicine · doi:10.1038/nm0709-726 · Cited by 30 · see citing works

Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis

Lang, S., Manning, N., Armstrong, N., et al. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.657299 · Cited by 27 · see citing works

The Glycophorin A Transmembrane Sequence within Integrin αvβ3 Creates a Non-Signaling Integrin with Low Basal Affinity That Is Strongly Adhesive under Force

Müller, M. A., Opfer, J., Brunie, L., Volkhardt, L. A., Sinner, E., Boettiger, D. C., Bochen, A., Kessler, H., Gottschalk, K., & Reuning, U. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.05.020 · Cited by 26 · see citing works

Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents

Полищук, П. Г., Samoylenko, G. V., Khristova, T. M., Krysko, O. L., Кабанова, Т. А., Kabanov, V. M., Kornylov, A. Y., Klimchuk, O., Langer, T., Andronati, S. A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00865 · Cited by 23 · see citing works

A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor

Jiang, J., McCoy, J. G., Shen, M., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.122 · Cited by 21 · see citing works

Structure-based virtual screening of small-molecule antagonists of platelet integrin αIIbβ3 that do not prime the receptor to bind ligand

Negri, A., Li, J., Naini, S., Coller, B. S., & Filizola, M. (2012) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-012-9594-6 · Cited by 20 · see citing works

How abciximab might be clinically useful

Usta, C., Turgut, N. T., & Bedel, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.213 · Cited by 18 · see citing works

Translating from the rivers of Babylon to the coronary bloodstream.

Coller, B. (2012) · Journal of Clinical Investigation · doi:10.1172/jci66867 · Cited by 17 · see citing works

Cytoplasmic salt bridge formation in integrin αvß3 stabilizes its inactive state affecting integrin-mediated cell biological effects

Müller, M. A., Brunie, L., Bächer, A.-S., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.07.013 · Cited by 16 · see citing works

Discovery of small molecule inhibitors of integrin αvβ3 through structure-based virtual screening

Zhou, Y. M., Peng, H., Ji, Q., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.061 · Cited by 13 · see citing works

Novel inhibitors of the αvβ3 integrin—lead identification strategy

Elliot, D., Henshaw, E., MacFaul, P. A., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.041 · Cited by 12 · see citing works

UR-3216: A New Generation Oral Platelet GPIIb / IIIa Antagonist

Aga, Y., Baba, K., Tam, S. H., et al. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043384592 · Cited by 12 · see citing works

UR‐3216: A Manageable Oral GPIIb/IIIa Antagonist

Baba, K., Aga, Y., Nakanishi, T., et al. (2001) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2001.tb00181.x · Cited by 10 · see citing works

Discovery of novel antagonists of glycoprotein IIb/IIIa-mediated platelet aggregation through virtual screening

Wang, Y., Zhao, Y., Sun, R., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.01.053 · Cited by 9 · see citing works

Synthesis, biological evaluation and molecular docking studies of 2-piperazin-1-yl-quinazolines as platelet aggregation inhibitors and ligands of integrin αIIbβ3

Krysko, A. A., Kornylov, A. Y., Полищук, П. Г., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.011 · Cited by 7 · see citing works

Eptifibatide in Coronary Intervention

Sherwood, M. W., & Tcheng, J. E. (2015) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.115.002340 · Cited by 1 · see citing works

Anti-angiogenic mechanism of IPS-05002, a novel antagonist against integrin a5β1, determined by ProteoChip-based antibody array

Kim, M. N., & Kang, I. (2016) · BioChip Journal · doi:10.1007/s13206-016-0303-8 · Cited by 1 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

Integrins as a drug target in liver fibrosis

Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022) · Liver International · doi:10.1111/liv.15157 · Cited by 74 · see citing works

Integrins : molecular and biological responses to the extracellular matrix

Cheresh, D. A., & Mecham, R. P. (1994) · Cited by 67 · see citing works

Genetic disruption of the kindlin-3/β1-integrin interaction results in defective β1-integrin dependent platelet adhesion and granula secretion

Petzold, T. (2013) · mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich)

Differences in α–β transmembrane domain interactions among integrins enable diverging integrin signaling

Kim, C., & Kim, M. C. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.05.115 · Cited by 9 · see citing works

Insights into Protein–Ligand Interactions in Integrin Complexes: Advances in Structure Determinations

Zheng, Y., & Leftheris, K. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01869 · Cited by 40 · see citing works

Factors That Influence the Homo- and Hetero-Oligomerization of the Leukocyte Integrin Transmembrane Domains

Span, L. M., Grigoryan, G., BENNETT, J. S., et al. (2008) · Blood · doi:10.1182/blood.v112.11.3556.3556